close
Add to watchlist
MAP Pharmaceuticals Inc (MAPP)
MAP Pharmaceuticals, Inc., a development stage company, engages in developing drug candidates to treat local respiratory and treatable diseases primarily in the United States. The company develops inhalable drug particles to facilitate pulmonary delivery. Its proprietary product candidates in clinical development include Unit Dose Budesonide, a nebulized version of budesonide for the treatment of asthma in children; and MAP0004, an orally inhaled version of dihydroergotamine for the treatment of migraine. The company's product portfolio also includes the earlier stage product candidates, which include MAP0005, an inhaled corticosteroid and beta-agonist for the treatment of asthma and chronic obstructive pulmonary disease; and MAP0001, a formulation of insulin for the treatment of Type 1 and Type 2 diabetes through pulmonary delivery using Tempo inhaler. It has a collaborations and license agreements with AstraZeneca, Elan Pharma International, Nektar Therapeutics, and Xemplar Pharmaceuticals. MAP Pharmaceuticals was founded in 2003 and is headquartered in Mountain View, California.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 16.12 |
| Volume | 553731 |
| Volume Avg | 157989 |
| 52 Week High | 17.92 |
| 52 Week Low | 10.54 |
| PE | 83.77 |
| PE (group average) | N/A |
| EPS Year | 0.20 |
| EPS change Q/Q | -1000% |
| EPS change Q/Q Yr ago | -1000% |
| EPS change Q/Q next Q est | -1000% |
| EPS change Y/Y | -45.45% |
| REV change Q/Q | -100% |
| REV change Q/Q Yr ago | -100% |
| EPS next Q est | -0.36 |
| EPS next Y est | -0.03 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |